Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo ... Novo has struggled to stay competitive with Eli Lilly LLY in developing the next ...

The small, 48-subject study – published ... in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing on ...

Novo Nordisk's amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo ... Novo Nordisk has struggled to stay competitive with Eli Lilly in developing the next generation ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before ...

Eli Lilly has thinned its pipeline ... the active ingredient in Mounjaro and Zepbound, but the GLP-1 candidate emerged as the more promising program. Lilly maintained an interest in the mechanism ...

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its way, this may be the future of obesity care.

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Weaker than expected data from the trial was a blow to Novo’s ambitions to find a more powerful competitor to Lilly’s ... mimics gut hormone GLP-1, with a separate molecule called cagrilintide ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Here are the small steps they're taking this year to get there. There is only one GLP-1 pill on the market, and it's not as effective as Ozempic for weight loss.Grace Cary/Getty Images Eli Lilly ...